The Top 10 Pharmaceutical Companies in 2026: Trends and Strategic Indicators
“In 2026, the world’s ten largest pharmaceutical companies will account for more than $500 billion in combined revenue, representing approximately 35% of the global pharmaceutical market, which is estimated at $1.5 trillion according to IQVIA (2026).”
In 2026, the ranking of global pharmaceutical companies is undergoing a shakeup. Johnson & Johnson remains in the lead with guidance of $100 to $101 billion, but Eli Lilly (boosted by Mounjaro and Zepbound) is closing the gap at a pace the industry did not anticipate.
This page compiles data from quarterly reports: 2025 results (already published), 2026 guidance announced by each group, and Q1–Q4 results as they are released. Last updated: March 29, 2026.
Prospective analysis · CDG Conseil
M&A — Halda $3 billion (oncology RIPTAC)
OTTAVA submitted to the FDA (surgical robot)
J&J is aiming for an unprecedented milestone: $100 billion in sales by 2026. The machinery is well-oiled: Darzalex and Rybrevant drive oncology, Tremfya stabilizes immunology, and MedTech (Shockwave, electrophysiology) is up 5.4%. Two recent acquisitions are expanding the pipeline in neuroscience (Intra-Cellular, Caplyta) and solid-tumor oncology (Halda, RIPTAC technology). No change in strategy: J&J is capitalizing on its sector diversification, which is unique among Big Pharma.
Risk — GLP-1 price pressure in China + competition from Novo’s oral product
$50+ billion invested in US manufacturing over 5 years
2026 marks Eli Lilly’s pivot to oral GLP-1s. The FDA submission of orforglipron (Q1 2026) and its likely approval in Q2 open up a new segment of patients resistant to injections. Competition is intensifying, Novo Nordisk launched its Wegovy pill this quarter, but Lilly has a significant manufacturing advantage (small molecule, room-temperature stability, $1.5 billion in pre-launch inventory). Key risk: price pressure from insurers and Medicare Part D.
Keytruda SC approved — anti-biosimilar defense 2028
Verona Pharma acquisition $10B (COPD — Ohtuvayre)
Gardasil China still underperforming
Merck is entering a phase of accelerated reshaping. Keytruda still accounts for 49% of pharmaceutical sales: its patent expiry in 2028 is the central variable of the entire 2026 strategy. The subcutaneous formulation approved in 2025 is a solid tactical response. In parallel, 6,000 positions have been cut with $3B in savings targeted by 2027. The long-term goal – $70B in sales by 2030 – rests on Winrevair (cardiology), Capvaxive (pneumonia) and the integration of Verona Pharma.
Eliquis — loss of exclusivity 2026–2028
RFK Jr. / HHS — uncertainty on US vaccine policy
SSGJ-707 (PD-1/VEGF bispecific) — Phase III initiated
Pfizer’s 2026 guidance (essentially flat or slightly down) confirms that the post-Covid transition is taking time. Two major patent expiries weigh on the outlook: Eliquis (2026–2028) and Prevnar (heightened competition). The $10B Metsera acquisition is a bet on long-acting GLP-1, but revenues will not materialize before 2028 at the earliest. Pfizer has also committed to $70B in US manufacturing investment as much a political commitment as an industrial one.
Orna Therapeutics — in vivo CAR-T (Feb. 2026)
Cerevel / emraclidine — Phase II failure (schizophrenia)
Skyrizi + Rinvoq — double-digit growth confirmed
AbbVie is the most-cited example of a successful post-blockbuster transition: Skyrizi and Rinvoq are absorbing the Humira decline. The 2026 momentum remains favorable, driven by indication extensions and the growing neuroscience franchise. The Gilgamesh acquisition (DMT, depression) is risky but strategically coherent ; AbbVie is the only Big Pharma betting on psychedelics. The Cerevel setback with emraclidine in schizophrenia, however, leaves a gap in neuropsychiatry that the Orna (in vivo CAR-T) deal does not directly fill.
$5.3B CSPC (AI + small molecules for chronic diseases)
20+ Phase III readouts expected in 2026
$80B 2030 target reaffirmed
AstraZeneca executes its strategy with a consistency rare in the sector. 16 blockbusters in 2025, 20+ targeted by 2030. The construction of a $4.5B site in Virginia (dedicated to oral GLP-1s, ADCs and anti-PCSK9 molecules) confirms a diversification into metabolic disease. The CSPC partnership for $5.3B (AI + small molecules) signals entry into chronic diseases via China. Few companies combine so many simultaneous growth vectors.
Tourmaline Bio $1.4B (inflammatory cardiovascular)
427 layoffs NJ — ahead of Entresto patent loss 2027
Cosentyx LOE 2025–2027 — biosimilar exposure
Novartis still posts solid growth but is racing against the clock. Entresto (2027) and Cosentyx (2025–2027) together represent over $15B in annual sales: their progressive loss of exclusivity is the central constraint. The $12B Avidity acquisition (RNA therapeutics for muscular dystrophies) is the most ambitious response: it opens a new modality with high potential, but commercial revenues are not expected before 2028–2030.
Zealand Pharma — adjacent GLP-1 collaboration (2025)
SBX (next-gen sequencing) — direct confrontation with Illumina
China Diagnostics: pricing reforms still in effect
Roche maintains a balance few competitors can match: a Pharmaceuticals division (Vabysmo, Hemlibra, Ocrevus) advancing at +9% CER, and a Diagnostics division absorbing Chinese pricing pressure. The 89bio acquisition positions Roche in MASH, a market seeing renewed momentum. More discreet but strategic: SBX next-gen sequencing technology, which draws Roche into a legal and commercial duel with Illumina. A solid comeback after years of biosimilar headwinds.
Positive CHMP — Dupixent children CSU (Feb. 2026)
Tolebrutinib — primary progressive MS failure (Dec. 2025)
UBS downgrade to Neutral — pipeline “below average”
Sanofi has a balance problem: Dupixent accounts for approximately 34% of total revenue and continues to grow at +32%, but its patent expires around 2031–2033. The tolebrutinib failure in primary progressive MS in December 2025 hardened analyst sentiment. UBS downgraded its recommendation to Neutral, judging that the replacement pipeline lacks depth. Amlitelimab (atopic dermatitis) is the main successor candidate, with an FDA decision expected during 2026.
Cobenfy adjunctive Phase III failed — Alzheimer’s data delayed to late 2026
Orbital Therapeutics — in vivo CAR-T
Growth Portfolio +16% Q4 2025 — 10+ launches targeted over 5 years
BMS is in the most precarious position in the ranking. Its Legacy Portfolio (Revlimid, Sprycel, Eliquis) is losing exclusivity faster than the Growth Portfolio can compensate. The 2026 guidance, between $46 and $47.5B, marks a real contraction for the first time. The Cobenfy failure as an adjunctive schizophrenia treatment and the delay of Alzheimer’s data until late 2026 undermine the positive narrative. CEO Boerner is banking on 10+ launches by 2030, but the horizon remains distant.
Ranking of pharmaceutical companies in 2026: current state of play
| # | Laboratory | Revenue 2025 (base) | Guidance 2026 | Growth 2025 | Revenue for T1 2026 | Driver product |
|---|---|---|---|---|---|---|
| 1 | Johnson & Johnson | $94,2 Md | ~$100,5 Md | +6,0 % | Available in April 2026 | Darzalex · MedTech |
| 2 | Eli Lilly | $65,2 Md | ~$78–83 Md est. | +44,7 % | Available in April 2026 | Mounjaro · Zepbound |
| 3 | Merck (MSD) | $65,0 Md | $65,5–67,0 Md | +1,3 % | Available in April 2026 | Keytruda |
| 4 | Pfizer | $62,6 Md | $61,0–64,0 Md | −1,7 % | Available in April 2026 | Eliquis · Vyndaqel |
| 5 | AbbVie | $61,2 Md | ~$65–67 Md est. | +8,6 % | Available in April 2026 | Skyrizi · Rinvoq |
| 6 | AstraZeneca | $58,7 Md | ~$63–65 Md est. | +8 % | Available in April 2026 | Tagrisso · Enhertu |
| 7 | Novartis | $54,5 Md | ~$57–59 Md est. | +8 % | Available in April 2026 | Cosentyx · Entresto |
| 8 | Roche | CHF 61,5 Md | +7–8 % CER est. | +7 % | Available in April 2026 | Vabysmo · Hemlibra |
| 9 | Sanofi | €43,6 Md | +8–9 % CER est. | +9,9 % | Available in April 2026 | Dupixent · Beyfortus |
| 10 | Bristol-Myers Squibb | $48,2 Md | $46–47,5 Md | ≈ stable | Available in April 2026 | Eliquis · Opdivo |
→ The “Q1 2026 Revenue” column and subsequent columns will be filled in as quarterly results are published (from April 2026 onwards). The 2026 estimates are calculated from the official guidance communicated by each group in their 2025 annual results.
What this ranking means for pharma recruitment in 2026
The pharmaceutical giants’ ranking should not be read merely as a financial barometer. For industry professionals and hiring companies alike, it maps the key forces shaping the job market in the months ahead.
The data we collected across 255 completed placements between November 2022 and October 2025 allows us to cross-reference economic rankings with ground-level reality.
→ Expanding companies are recruiting experienced profiles
The double-digit growth of AstraZeneca (+18%), Eli Lilly (+32%) and Bristol Myers Squibb (+9%) translates directly into increased demand for specialists in clinical development, regulatory affairs and market access. These companies, driven by oncology expansion or the anti-obesity treatment boom, need managers who can hit the ground running in senior roles. This is exactly the profile we recruit: 58% of our placed candidates have more than 11 years of experience, and 25% more than 20.
→ Medical devices: our top recruitment sector
An often-overlooked fact: medical devices account for 37% of our placements over three years, ahead of the pharmaceutical industry proper (24%). The boundary between pharma and medtech is blurring — groups like Johnson & Johnson, active on both fronts, embody this convergence. Profiles that move fluidly between both worlds, particularly in regulatory affairs (MDR, IVDR) and market access, are especially sought after.
→ 78% of recruited talent were already employed
This is one of the most significant findings from our analysis: 78% of the candidates we placed were not actively looking for a new role at the time we approached them. In a sector where expert profiles are scarce and loyal to their employers, executive search accounts for 46% of our recruitment sources — well ahead of traditional job postings.
For pharmaceutical companies hiring in 2026, this means one concrete thing: the best candidates will not apply to your job offers. You have to go and find them.
→ The most in-demand profiles in 2026
Based on ongoing assignments and trends observed across our client portfolio, the most sought-after roles in the pharmaceutical and biotech industry are:
- Medical Science Liaison (MSL) – demand remains strong, driven by new molecule launches in oncology and immunology
- Regulatory Affairs – every new product and every label extension generates needs; increasing European regulatory complexity adds further pressure
- Market Access and health economics – with growing payer pressure on pricing, these profiles have become strategically critical for mid-sized companies
- Pharmacovigilance – post-marketing authorisation regulatory requirements are tightening; qualified profiles are in short supply
- Industry Physician / Medical Director – physicians transitioning into industry are increasingly common, but already experienced profiles remain rare
→ A geographically concentrated job market
Auvergne-Rhône-Alpes and Île-de-France account for 62% of our placements — a direct reflection of where the headquarters and R&D centres of major groups are located in France. For candidates based in other regions, mobility remains a decisive factor in accessing the most senior positions.
FAQ – pharmaceutical companies
Which pharma companies are hiring the most in France in 2026?
In 2026, the pharmaceutical companies hiring the most in France are primarily Sanofi, Pfizer France, MSD (Merck), AstraZeneca, Roche, Novartis, AbbVie, Ipsen and Servier. The most sought-after profiles cover Regulatory Affairs (RA), Quality (QA/QC), Clinical Development, Pharmacovigilance and Medical Affairs. Demand is also strong among contract manufacturers (CDMOs) such as Recipharm, Fareva and Delpharm. CDG Conseil, a specialist Life Sciences recruitment firm, supports these companies in their executive and leadership hiring across France and internationally through the INRALS network.
How is the global pharmaceutical market evolving in 2026?
In 2026, the global pharmaceutical market continues to grow steadily and is likely to exceed $1.5 trillion. Three major trends are shaping it: first, the GLP-1 analogue revolution for obesity and diabetes is generating unprecedented worldwide demand; second, precision oncology (bispecific antibodies, ADCs, radioligands) dominates R&D pipelines and accounts for more than 40% of global pharmaceutical R&D spending; third, the 2027–2030 patent cliff (Keytruda, Entresto, Cosentyx) is pushing companies to accelerate acquisitions and launches. Global growth is expected at 7 to 9% in 2026.
Will Eli Lilly overtake Johnson & Johnson in the global ranking?
Eli Lilly is on track to overtake Johnson & Johnson between 2027 and 2028 if the current trajectory holds. In 2025, Lilly grew by +44.7% to reach $65.2 billion, compared to $94.2 billion for J&J (+6%). The remaining gap stands at approximately $29 billion. With Mounjaro and Zepbound already representing 56% of Lilly’s revenue and global demand still largely unmet, annual growth of 20 to 30% is credible. The overtaking will depend on Lilly’s manufacturing capacity and the pace of reimbursement coverage expansion in Europe and China.
Looking to hire?
Are you a healthcare or pharma industry professional looking to explore new opportunities? Submit your application — 78% of our placements involve candidates who were not actively looking.
Are you hiring in the pharmaceutical, biotech or medtech sector? Contact our team.
